Balderton leads $30m series-D for Sophia Genetics

360 Capital Partners and existing investors Invoke Capital and Alychio also took part in the round.

The fresh capital will be used to develop the company's technology as well as its marketing to hospitals. Sophia will also expand its staff.

Balderton stated it was attracted to Sophia's focus on two rapidly changing technologies, genomic medicine and artificial intelligence, and sees the opportunity to build a defining operating system for these technologies.

Previous funding
The company received seed funding of €653,000 in 2012. In April 2013, Sophia raised CHF 2.8m in a series-A funding round.

It was first backed by institutional money in 2014 when Invoke, Swisscom and Endeavour Vision took part in a $13.75m series-B for the company.

Marc Coucke's pharmaceutical investment firm Alychio then led a $15m series-C in December 2013.

Company
Founded in March 2011 in the scientific incubator Incubation Park – part of the Ecole Polytechnique Fédérale de Lausanne – Sophia uses algorithms to diagnose genetic diseases. The technology is used daily in 334 hospitals in 53 countries and has tested more than 125,000 patients to date. It employs 150 people in its three offices in Laussane, Cambridge and Montpellier.

People
Balderton Capital – James Wise (partner).
360 Capital Partners – Nicolas Autret (partner).
Sophia Genetics – Jurgi Camblong (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Balderton Capital